PREDIMED: Mediterranean Diet + EVOO Linked to 68% Lower Breast Cancer Incidence

This randomized clinical trial from Spain tested whether a Mediterranean diet supplemented with extra virgin olive oil could reduce the incidence of invasive breast cancer in women at high cardiovascular risk. Published in JAMA Internal Medicine, the PREDIMED breast cancer analysis found that the EVOO group had a 68% lower hazard of invasive breast cancer compared with the low-fat control diet -- the first randomized trial to identify a long-term dietary intervention effect on breast cancer incidence. The intervention was built around extra virgin olive oil as the primary added fat.

Why This Study Matters

Most of what we know about diet and breast cancer comes from observational studies. Women who eat a Mediterranean-style diet have lower breast cancer rates, but observational data can't separate the diet from the lifestyle that usually surrounds it -- the exercise, the lower processed-food intake, the higher socioeconomic status that often comes with health-conscious eating.

PREDIMED was different. It was a randomized controlled trial. 4,152 women aged 60 to 80 who were at high cardiovascular risk -- but free of breast cancer at baseline -- were assigned at random to one of three arms: a Mediterranean diet supplemented with EVOO, a Mediterranean diet supplemented with mixed nuts, or advice to follow a low-fat diet (the control). Randomization meant the three groups were balanced at baseline for the confounders observational studies struggle with.

The result was the first randomized evidence that a dietary intervention could reduce invasive breast cancer incidence. The EVOO arm showed a 68% lower hazard versus control. The size of that effect -- and the fact that it came from a trial rather than a cohort -- is what makes this analysis worth understanding in detail.

How It Was Designed

The basics: 4,152 women, 4.8-year median follow-up, three-arm randomized trial conducted across primary care centers in Spain between 2003 and 2009. Breast cancer incidence was a prespecified secondary outcome -- meaning the researchers committed to measuring it before data collection began, not after seeing the results.

The EVOO arm received approximately 1 liter of polyphenol-rich extra virgin olive oil per week, free of charge, with instructions to use it as the primary added fat for cooking, salads, and bread. The nut arm received 30 grams per day of mixed nuts (walnuts, almonds, hazelnuts). The control arm received written and verbal advice to reduce all dietary fat, including a tri-monthly leaflet -- but no food was supplied. Compliance was monitored through biomarkers (urinary hydroxytyrosol for the EVOO arm, plasma alpha-linolenic acid for the nuts arm).

Cox proportional-hazards models were adjusted for age, family history of breast cancer, prior personal history of benign disease, alcohol intake, smoking, BMI, physical activity, education, parity, age at menarche, age at first pregnancy, age at menopause, and use of hormone replacement therapy. The analyses excluded women with a prior history of breast cancer (n = 130), leaving 4,152 in the primary analysis.

What They Found

After a median follow-up of 4.8 years, 35 confirmed incident cases of breast cancer were identified. Observed rates per 1,000 person-years were 1.1 in the EVOO arm, 1.8 in the nuts arm, and 2.9 in the control arm. The multivariable-adjusted hazard ratios versus control were:

Intervention	Hazard Ratio (95% CI)	Risk Reduction	What It Measures
Med diet + EVOO	0.32 (0.13-0.79)	68% lower	Invasive breast cancer incidence
Med diet + nuts	0.59 (0.26-1.35)	41% lower (NS)	Invasive breast cancer incidence
+5% energy from EVOO	0.72 (0.57-0.90)	28% lower per 5%	Dose-response with cumulative EVOO intake

Green indicates a favorable direction vs. low-fat control. The EVOO arm reached statistical significance; the nut arm trended in the same direction but did not.

The dose-response analysis is worth highlighting. When the researchers modeled cumulative EVOO intake -- updated yearly across the trial -- each additional 5% of total daily calories from EVOO was associated with a 28% lower hazard of breast cancer (HR 0.72; 95% CI 0.57-0.90). That's a linear, biologically coherent dose-response that strengthens the case for a causal interpretation.

Reading the Results

The three groupings break down by intervention and by mechanism.

EVOO arm (68% lower). This is the headline result, and it's the largest single intervention effect ever reported in a randomized trial for breast cancer prevention through diet. The confidence interval (0.13-0.79) is wide because only 35 events occurred across the whole trial -- but the lower bound still excludes 1.0, meaning the result is statistically significant. The mechanism is plausible: olive oil polyphenols (particularly hydroxytyrosol and oleocanthal) have shown anti-proliferative and anti-inflammatory effects in laboratory and animal models of breast cancer, and the monounsaturated fat profile of olive oil has been linked to favorable changes in estrogen metabolism.

Mixed nuts arm (41% lower, not significant). The point estimate is in the same direction as EVOO, but the confidence interval crosses 1.0 (0.26-1.35). Two interpretations are consistent with the data: either nuts have a smaller true effect than EVOO, or the trial was underpowered to detect a moderate effect with only 35 events. The data don't distinguish between those.

Dose-response (28% lower per 5% energy from EVOO). This is the cleanest signal in the analysis. A linear relationship between exposure and outcome -- holding for cumulative intake updated across the trial -- is the kind of finding that's hardest to explain away as confounding. It supports the interpretation that EVOO itself, rather than some unmeasured aspect of the Mediterranean diet, is driving the effect.

What Didn't Change

The trial was not designed primarily to detect breast cancer; this was a prespecified secondary outcome, and only 35 events were recorded. The wide confidence intervals reflect that. The trial also did not measure tumor subtype, hormone receptor status, or breast cancer mortality -- only invasive breast cancer incidence. The results don't tell us whether EVOO affects estrogen receptor-positive vs. negative tumors differently, and they don't tell us whether the intervention extends to women below age 60 or to women without elevated cardiovascular risk.

The authors themselves note that these findings come from a secondary analysis based on few incident cases and need confirmation in longer, larger trials. That caveat is honest and worth holding alongside the headline number.

Broader Context

PREDIMED is the largest randomized dietary trial ever conducted on Mediterranean diet patterns. Its primary outcome -- published separately -- showed a 30% reduction in major cardiovascular events with the Mediterranean diet supplemented with EVOO compared to the low-fat control. The breast cancer analysis extends that signal into a cancer endpoint, using the same randomized framework.

The 2011 European Food Safety Authority opinion (Regulation 432/2012) authorized a health claim for olive oil polyphenols and protection of blood lipids from oxidative damage, at a daily intake of 5 mg of hydroxytyrosol and its derivatives. EFSA has not authorized a cancer-related claim for olive oil polyphenols, and this trial's authors do not propose one. The mechanism for breast cancer prevention remains an active area of research; what PREDIMED contributes is the strongest randomized evidence to date that the intervention itself reduces incidence.

For context within the wider literature: observational cohorts including EPIC and the Three-City Study have consistently linked higher olive oil intake to lower cancer incidence and mortality across multiple sites. PREDIMED is the trial that demonstrates the association holds when intake is randomized rather than self-selected.

Related Research

Continue exploring olive oil and polyphenol science:

• PREDIMED Republished: Mediterranean Diet + EVOO Cut Major CV Events by 30%
• Italian Cohort: Olive Oil Linked to Lower Cancer, CV and All-Cause Mortality
• Olive Oil and Brain Health: 66% Lower Cognitive Impairment Risk in PREDIMED Trial

Source: View the original study on PubMed

Olivea's Dosage

The PREDIMED EVOO arm consumed approximately 1 liter of extra virgin olive oil per week -- roughly 4 tablespoons per day. Each tablespoon of Olivea extra virgin olive oil delivers approximately 14 grams of EVOO, well within the dose range used in the trial. Each Olivea capsule delivers over 20 mg of hydroxytyrosol per serving in an EVOO matrix; our most recent third-party certificate of analysis confirmed 23.5 mg per capsule.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.